GLP-1 plays an important role in glucose homeostasis and is secreted into the hepatic portal system in response to elevated glucose levels from food intake 10 , stimulating insulin synthesis and release from the pancreas 11
This is a pre-filled injection format of LY3437943, a triple agonist binding GIP, GLP-1 and glucagon receptors currently in Phase 3 trials expected to conclude in May 2026 [6][8]
This article is for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment
Weeks 5 to 8: 12.5 mg to 10 mg
For details on known side effects, see our retatrutide side effects guide
If your current prescriber does not offer this, asking for a referral to a registered dietitian who specializes in obesity medicine is a reasonable step